Senti Biosciences (NASDAQ:SNTI – Get Free Report) and Longeveron (NASDAQ:LGVN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Institutional and Insider Ownership
25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 11.2% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Risk & Volatility
Senti Biosciences has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senti Biosciences | 1 | 0 | 4 | 1 | 2.83 |
| Longeveron | 1 | 0 | 2 | 0 | 2.33 |
Senti Biosciences currently has a consensus price target of $9.00, suggesting a potential upside of 669.23%. Longeveron has a consensus price target of $6.50, suggesting a potential upside of 1,079.25%. Given Longeveron’s higher probable upside, analysts plainly believe Longeveron is more favorable than Senti Biosciences.
Profitability
This table compares Senti Biosciences and Longeveron’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senti Biosciences | N/A | -197.68% | -63.05% |
| Longeveron | -1,485.25% | -138.44% | -108.46% |
Valuation & Earnings
This table compares Senti Biosciences and Longeveron”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senti Biosciences | $2.56 million | 12.02 | -$52.79 million | ($3.33) | -0.35 |
| Longeveron | $2.39 million | 4.92 | -$15.97 million | ($1.06) | -0.52 |
Longeveron has lower revenue, but higher earnings than Senti Biosciences. Longeveron is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Senti Biosciences beats Longeveron on 10 of the 15 factors compared between the two stocks.
About Senti Biosciences
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Receive News & Ratings for Senti Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senti Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
